Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;31(10):1579-85.
doi: 10.3346/jkms.2016.31.10.1579.

Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea

Yoojoo Lim  1 , Jeong Ok Lee  1 , Soo Mee Bang  2
Affiliations

Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea

Yoojoo Lim et al. J Korean Med Sci. 2016 Oct.

Abstract

The nationwide statistical analysis of each disease of classical myeloproliferative neoplasm (MPN) in Korea has not been reported yet. To this end, we have analyzed incidence rates, survival rates and treatment pattern of polycythemia vera (PV), primary myelofibrosis (MF) and essential thrombocythemia (ET) using Korea National Cancer Incidence Database (KNCIDB) and Health Insurance Review and Assessment Service (HIRA) database. Between 2003 and 2011, a total of 4,342 new cases of MPN were reported to the KNCIDB. ET was the most common, followed by MF and PV. The crude incidence rates for PV, MF, and ET have increased during the period, reaching 0.40, 0.15, and 0.84 per 100,000, respectively. Five-year relative survival rate of all MPN patients was 89.3%, with lowest relative survival rate with MF (53.1%). The prevalence of each disease estimated from HIRA data also increased during the study period. Notably, ET was found to be most prevalent. The prescription rate of hydroxyurea and phlebotomy to PV, MF and ET patients remained constant over the period, and the prescription rate of hydroxyurea was higher in patients with age over 60 years. This is the first Korean nationwide statistics of MPN, using central registry data. This set of data can be utilized to compare the Korean MPN status to international data and guidelines.

Keywords: Incidence; Korea; Myeloproliferative Neoplasm; Prevalence; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
Relative frequency of MPN incidence in Korea, 2011. (A) Men. (B) Women.
Fig. 2
Fig. 2
Age-specific incidence rates of MPN in Korea, 2011. (A) Men. (B) Women.
Fig. 3
Fig. 3
The proportion of patients with prescription of hydroxyurea and phlebotomy. (A) Polycythemia vera. (B) Primary myelofibrosis. (C) Essential thrombocythemia.
See this image and copyright information in PMC

References

    1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–375. - PubMed
    1. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–1097. - PubMed
    1. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:171–173. - PubMed
    1. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55:595–600. - PubMed
    1. Mehta J, Wang H, Fryzek JP, Iqbal SU, Mesa R. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma. 2014;55:2368–2374. - PubMed

MeSH terms